Why Innodata Stock Tumbled by 10% Last Month It wasn't because of the quarterly earnings report it published that month.
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.
Cerebras Has a $25.4 Billion Backlog, and One OpenAI Agreement Is Behind Much of It The AI computing specialist's latest results were strong. The real story is a backlog worth almost 29 times this year's expected revenue.
CVB Financial Director Mike Maddox Buys 10,000 Shares Maddox's $220,300 purchase triples his direct equity stake, signaling confidence in the regional bank despite modest recent stock performance.
This eVTOL Stock Could Set Early Investors Up for Life Archer is gearing itself up to become a highly profitable eVTOL company.
Why Intel Stock Climbed This Week Dell's torrid revenue growth bodes well for the semiconductor leader.
Notional Finance Escrow Contract Loses $1.7M As Funds Move To Tornado Cash A Notional Finance escrow contract appears to have been exploited for roughly $1.7 million, with the stolen stablecoins converted into Ether and deposited
Unusual Machines CFO Brian Hoff Sells 11,413 Shares Despite the recent stock sale, the executive still owns over 341,000 shares.
AMD Committed Up to $5 Billion to Anthropic, and Anthropic's IPO Prospectus Is Reportedly Days Away The chipmaker's up-to-$5 billion pledge comes with conditions attached -- and the company on the receiving end is about to get a public price.
QuantumScape Stock Is Worth a Closer Look Right Now This solid-state battery maker's technology provides benefits to both the electric vehicle and artificial intelligence sectors.
Coca-Cola Stock at $88: Here's Why Investors Should Pause The stock of Coca-Cola's archrival and the behavior of a prominent shareholder strongly indicate it is a hold.
Can Dogecoin Reach $1 in the Next 12 Months? The hype and buzz around DOGE appear to be fading, making it a clear pitfall for investors.
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.
